Regencell Bioscience Holdings Limited (RGC)
USD 28.21
(-7.48%)
USD 28.21
(-7.48%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 219.51 Thousand USD | -65.28% |
| 2023 | 632.32 Thousand USD | -32.59% |
| 2022 | 938.03 Thousand USD | -78.38% |
| 2021 | 4.33 Million USD | 37.06% |
| 2020 | 3.16 Million USD | 52.03% |
| 2019 | 2.08 Million USD | -99.94% |
| 2018 | 3.69 Billion USD | 6.14% |
| 2017 | 3.48 Billion USD | -0.72% |
| 2016 | 3.5 Billion USD | 2.2% |
| 2015 | 3.43 Billion USD | 0.0% |
| 2013 | 3.41 Billion USD | 17.61% |
| 2012 | 2.9 Billion USD | -2.57% |
| 2011 | 2.98 Billion USD | 3.41% |
| 2010 | 2.88 Billion USD | 1.53% |
| 2009 | 2.84 Billion USD | 0.0% |
| 2007 | 2.75 Billion USD | 10.61% |
| 2006 | 2.48 Billion USD | 0.73% |
| 2005 | 2.47 Billion USD | 47.7% |
| 2004 | 1.67 Billion USD | 0.0% |
| 2002 | 1.03 Billion USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 312.55 Thousand USD | -50.57% |
| 2024 Q2 | 312.55 Thousand USD | 0.0% |
| 2024 Q4 | 219.51 Thousand USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q2 | 873.78 Thousand USD | 0.0% |
| 2023 Q4 | 632.32 Thousand USD | 0.0% |
| 2023 FY | 632.32 Thousand USD | -32.59% |
| 2023 Q3 | 632.32 Thousand USD | -27.63% |
| 2022 Q4 | 938.03 Thousand USD | 0.0% |
| 2022 FY | 938.03 Thousand USD | -78.38% |
| 2022 Q3 | 938.03 Thousand USD | -31.22% |
| 2022 Q1 | 1.36 Million USD | -68.56% |
| 2022 Q2 | 1.36 Million USD | 0.0% |
| 2021 Q1 | 3.58 Million USD | 13.28% |
| 2021 FY | 4.33 Million USD | 37.06% |
| 2021 Q4 | 4.33 Million USD | 0.0% |
| 2021 Q2 | 3.58 Million USD | 0.0% |
| 2021 Q3 | 4.33 Million USD | 20.99% |
| 2020 Q3 | 3.16 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | 3.16 Million USD | 52.03% |
| 2020 Q4 | 3.16 Million USD | 0.0% |
| 2019 FY | 2.08 Million USD | -99.94% |
| 2018 Q1 | 3.52 Billion USD | -1.56% |
| 2018 Q2 | 3.69 Billion USD | 4.86% |
| 2018 FY | 3.69 Billion USD | 6.14% |
| 2017 Q4 | 3.58 Billion USD | 2.03% |
| 2017 Q1 | 3.33 Billion USD | -3.08% |
| 2017 Q2 | 3.48 Billion USD | 4.36% |
| 2017 Q3 | 3.51 Billion USD | 0.79% |
| 2017 FY | 3.48 Billion USD | -0.72% |
| 2016 Q1 | 3.31 Billion USD | -4.9% |
| 2016 FY | 3.5 Billion USD | 2.2% |
| 2016 Q4 | 3.44 Billion USD | -0.57% |
| 2016 Q3 | 3.46 Billion USD | -1.28% |
| 2016 Q2 | 3.5 Billion USD | 6.0% |
| 2015 FY | 3.43 Billion USD | 0.0% |
| 2015 Q1 | 3.3 Billion USD | -3.44% |
| 2015 Q4 | 3.48 Billion USD | 2.53% |
| 2015 Q3 | 3.39 Billion USD | -1.12% |
| 2015 Q2 | 3.43 Billion USD | 3.87% |
| 2014 Q2 | 3.41 Billion USD | 8.0% |
| 2014 Q4 | 3.42 Billion USD | -3.18% |
| 2014 Q3 | 3.53 Billion USD | 3.46% |
| 2014 Q1 | 3.16 Billion USD | -4.22% |
| 2013 FY | 3.41 Billion USD | 17.61% |
| 2013 Q4 | 3.3 Billion USD | 4.7% |
| 2013 Q2 | 2.9 Billion USD | 5.73% |
| 2013 Q3 | 3.15 Billion USD | 8.59% |
| 2013 Q1 | 2.74 Billion USD | -3.45% |
| 2012 Q2 | 2.91 Billion USD | 3.41% |
| 2012 FY | 2.9 Billion USD | -2.57% |
| 2012 Q4 | 2.84 Billion USD | -0.38% |
| 2012 Q3 | 2.85 Billion USD | -1.86% |
| 2012 Q1 | 2.81 Billion USD | -3.1% |
| 2011 Q2 | 2.98 Billion USD | 1.54% |
| 2011 Q1 | 2.93 Billion USD | 2.81% |
| 2011 Q3 | 2.86 Billion USD | -3.96% |
| 2011 FY | 2.98 Billion USD | 3.41% |
| 2011 Q4 | 2.9 Billion USD | 1.45% |
| 2010 Q1 | 2.77 Billion USD | -3.62% |
| 2010 Q3 | 2.84 Billion USD | -1.23% |
| 2010 Q4 | 2.85 Billion USD | 0.29% |
| 2010 Q2 | 2.88 Billion USD | 4.1% |
| 2010 FY | 2.88 Billion USD | 1.53% |
| 2009 FY | 2.84 Billion USD | 0.0% |
| 2009 Q1 | 2.78 Billion USD | -4.14% |
| 2009 Q2 | 2.84 Billion USD | 2.16% |
| 2009 Q3 | 2.8 Billion USD | -1.13% |
| 2009 Q4 | 2.87 Billion USD | 2.35% |
| 2008 Q4 | 2.9 Billion USD | 2.91% |
| 2008 Q2 | 2.75 Billion USD | 2.49% |
| 2008 Q3 | 2.81 Billion USD | 2.4% |
| 2008 Q1 | 2.68 Billion USD | -3.14% |
| 2007 Q4 | 2.77 Billion USD | -13.72% |
| 2007 FY | 2.75 Billion USD | 10.61% |
| 2007 Q3 | 3.21 Billion USD | 29.13% |
| 2007 Q2 | 2.48 Billion USD | 4.98% |
| 2007 Q1 | 2.37 Billion USD | -3.03% |
| 2006 Q4 | 2.44 Billion USD | 1.2% |
| 2006 Q3 | 2.41 Billion USD | -3.4% |
| 2006 Q2 | 2.5 Billion USD | 4.56% |
| 2006 Q1 | 2.39 Billion USD | -1.28% |
| 2006 FY | 2.48 Billion USD | 0.73% |
| 2005 Q2 | 2.47 Billion USD | 5.33% |
| 2005 FY | 2.47 Billion USD | 47.7% |
| 2005 Q1 | 2.34 Billion USD | -2.09% |
| 2005 Q3 | 2.4 Billion USD | -2.83% |
| 2005 Q4 | 2.42 Billion USD | 0.92% |
| 2004 FY | 1.67 Billion USD | 0.0% |
| 2004 Q2 | 1.67 Billion USD | 6.09% |
| 2004 Q1 | 1.57 Billion USD | -33.43% |
| 2004 Q4 | 2.39 Billion USD | 51.45% |
| 2004 Q3 | 1.58 Billion USD | -5.44% |
| 2003 Q4 | 2.36 Billion USD | 135.72% |
| 2003 Q1 | 1.07 Billion USD | -6.26% |
| 2003 Q2 | 1.03 Billion USD | -3.9% |
| 2003 Q3 | 1 Billion USD | -2.99% |
| 2002 Q3 | 1.41 Billion USD | 0.0% |
| 2002 FY | 1.03 Billion USD | 0.0% |
| 2002 Q4 | 1.15 Billion USD | -18.65% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 99.84% |
| PainReform Ltd. | 2.69 Million USD | 91.843% |
| Alvotech | 1.88 Billion USD | 99.988% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 99.977% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 99.953% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 99.866% |
| Journey Medical Corporation | 56.49 Million USD | 99.611% |
| Dynavax Technologies Corporation | 375.02 Million USD | 99.941% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 99.967% |
| Bright Green Corporation | 6.43 Million USD | 96.59% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 99.969% |
| Embecta Corp. | 2.03 Billion USD | 99.989% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | 96.425% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | 96.425% |
| SCYNEXIS, Inc. | 55.45 Million USD | 99.604% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | 98.97% |
| Silver Spike Investment Corp. | 3 Million USD | 92.707% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | 97.613% |
| Alpha Teknova, Inc. | 38.55 Million USD | 99.431% |
| Safety Shot Inc | 3.89 Million USD | 94.36% |
| Procaps Group, S.A. | 462.06 Million USD | 99.952% |
| Cosmos Health Inc. | 30.25 Million USD | 99.274% |
| Theratechnologies Inc. | 98.63 Million USD | 99.777% |
| Harrow Health, Inc. | 241.75 Million USD | 99.909% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | 97.493% |
| Biofrontera Inc. | 23.13 Million USD | 99.051% |
| DURECT Corporation | 30.4 Million USD | 99.278% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 99.955% |
| Cronos Group Inc. | 43.73 Million USD | 99.498% |
| OptiNose, Inc. | 194.33 Million USD | 99.887% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 99.973% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 99.547% |
| RedHill Biopharma Ltd. | 20.97 Million USD | 98.954% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 99.879% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | 94.181% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 99.582% |
| Radius Health, Inc. | 804.29 Million USD | 99.973% |
| Universe Pharmaceuticals INC | 13.75 Million USD | 98.404% |
| ProPhase Labs, Inc. | 42.54 Million USD | 99.484% |
| Phibro Animal Health Corporation | 725.54 Million USD | 99.97% |
| Procaps Group S.A. | 462.06 Million USD | 99.952% |
| TherapeuticsMD, Inc. | 14.02 Million USD | 98.435% |
| Viatris Inc. | 27.21 Billion USD | 99.999% |
| Rockwell Medical, Inc. | 30.88 Million USD | 99.289% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 99.757% |
| SIGA Technologies, Inc. | 57.97 Million USD | 99.621% |
| Tilray Brands, Inc. | 892.11 Million USD | 99.975% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 99.9% |
| Shineco, Inc. | 47.6 Million USD | 99.539% |
| PetIQ, Inc. | 645.22 Million USD | 99.966% |
| Incannex Healthcare Limited | 5.83 Million USD | 96.235% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.978% |
| Alimera Sciences, Inc. | 107.35 Million USD | 99.796% |
| Assertio Holdings, Inc. | 148.41 Million USD | 99.852% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | 88.422% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | 96.876% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | 97.415% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 99.873% |
| Hempacco Co., Inc. | 18.82 Million USD | 98.834% |
| Talphera, Inc. | 6.29 Million USD | 96.51% |
| Alvotech | 1.88 Billion USD | 99.988% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 99.873% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 99.974% |
| Currenc Group, Inc. | 177.67 Million USD | 99.876% |
| Kamada Ltd. | 109.96 Million USD | 99.8% |
| Indivior PLC | 1.95 Billion USD | 99.989% |
| Evoke Pharma, Inc. | 9.64 Million USD | 97.725% |
| Flora Growth Corp. | 17.22 Million USD | 98.725% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | 97.415% |
| Evolus, Inc. | 209.68 Million USD | 99.895% |
| HUTCHMED (China) Limited | 536.38 Million USD | 99.959% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 99.975% |
| Akanda Corp. | 12.66 Million USD | 98.267% |